Figure 1 | Scientific Reports

Figure 1

From: Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of breast cancer and melanoma

Figure 1

High expression of SLAMF6 correlates with longer PFI and OS in breast cancer and melanoma. (A–C) Progression-free interval (PFI) (left) and overall survival (OS) (right) for high versus low SLAMF6 group in breast cancer (BRCA Primary) (A), primary melanoma (SKCM Primary) (B) and metastatic melanoma (SKCM Metastatic) cohort (C). P values were calculated by a log-rank (Mantel–Cox) test (A–C).

Back to article page